首页 国际期刊 医学期刊 期刊详情(非官网)
400-808-1701

Experimental Hematology & Oncology

Experimental Hematology & Oncology杂志,由BioMed Central出版,于2012年创刊,1 issue/year,出版语言English,ISSN:2162-3619,E-ISSN:2162-3619。

投稿咨询
Experimental Hematology & Oncology
Experimental Hematology & Oncology
Experimental Hematology & Oncology
SCI SCIE

杂志介绍

JCR分区
Q1
中科院分区
1区
影响因子
17.5
CiteScore
19.6
期刊收录
SCI、SCIE

Experimental Hematology & Oncology(中文译名:《实验血液学和肿瘤学》),ISSN:2162-3619,EISSN:2162-3619,是BioMed Central出版的国际性学术期刊,创刊于2012年,以1 issue/year形式稳定发行,2026年总发文量约92篇。该刊采用OA开放访问,学科归属为Medicine - Oncology。该刊是医学、肿瘤学领域的国际权威刊物,已被SCI(科学引文索引)、SCIE(科学引文索引扩展版)等国际主流学术数据库收录。2026年期刊影响因子达17.5,2025年期刊CiteScore为19.6,2025年期刊自引率约5.7%,在中科院期刊分区体系中位列医学大类1区TOP 期刊,在所属学科领域具备高学术影响力与国际认可度。Experimental Hematology & Oncology长期聚焦医学、肿瘤学及相关产业的技术应用前沿,平均审稿周期6 Weeks,审稿流程高效稳定。在稿件录用评判中,该刊将创新性与前沿性作为核心遴选标准,重点收录能够对医学、肿瘤学领域的落地与发展产生实质性推动价值的研究成果。

从全球发文格局来看,USACHINA MAINLAND、Iran、Italy、Canada、France、Norway等为核心发文国家与地区;ZHENGZHOU UNIVERSITYHUAZHONG UNIVERSITY OF SCIENCE & TECHNOLOGY、LOMA LINDA UNIVERSITY、UNIVERSITY OF CALIFORNIA SYSTEM、INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)、NEW YORK MEDICAL COLLEGE、ZHEJIANG UNIVERSITY等高校与科研机构是期刊的主要发文单位。

期刊评价

名词解释:

影响因子(Impact Factor, IF):指该期刊前两年发表的文章,在第三年的平均被引用次数。它反映了期刊的近期平均影响力和热度。

中科院分区:中科院分区表是国内主流的学术期刊分级评价工具,核心意义是建立跨学科可比的统一评价标尺,为职称评审、学位授予、科研立项等科研管理工作提供标准化量化依据,同时帮助科研人员筛选优质期刊、规避学术风险,适配国内本土化的科研评价需求。

期刊分区表

《新锐期刊分区表》(2026年3月发布)

大类学科 小类学科 Top期刊 综述期刊
医学
1区
ONCOLOGY 肿瘤学 HEMATOLOGY 血液学
1区 1区

期刊分区表(2025年3月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
2区
HEMATOLOGY 血液学 ONCOLOGY 肿瘤学
2区 2区

期刊分区表(2023年12月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
1区
HEMATOLOGY 血液学 ONCOLOGY 肿瘤学
2区 2区

JCR分区

2025-2026年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:HEMATOLOGY SCIE Q1 5 / 103

95.6

学科:ONCOLOGY SCIE Q1 19 / 333

94.4

学科:HEMATOLOGY SCIE Q1 6 / 103

94.66

学科:ONCOLOGY SCIE Q1 28 / 333

91.74

2023-2024年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:HEMATOLOGY SCIE Q1 9 / 97

91.2

学科:ONCOLOGY SCIE Q1 32 / 322

90.2

学科:HEMATOLOGY SCIE Q1 13 / 97

87.11

学科:ONCOLOGY SCIE Q1 36 / 322

88.98


中国学者近期发文

1
Decoding the spatiotemporal characteristics of ferroptosis: reshaping tumour therapeutic strategie

Author:Song, Lizhou; Shu, Yue; Zhou, Tian; Wang, Yi; Zhang, Haoling; Liao, Yan; Zhu, Chenglong; Zhang, Wangzheqi; Zou, Zui

Journal: EXPERIMENTAL HEMATOLOGY & ONCOLOGY. 2026; Vol. 15, Issue 1, pp. -. DOI: 10.1186/s40164-026-00773-5

2
Novel non-viral in vivo CAR-T therapies: latest updates from the 2025 ASH annual meeting (vol 15, 34, 2026

Author:Xue, Bin; Liu, Yifan; Liang, Aibin; Zhang, Wenjun

Journal: EXPERIMENTAL HEMATOLOGY & ONCOLOGY. 2026; Vol. 15, Issue 1, pp. -. DOI: 10.1186/s40164-026-00772-6

3
The novel retinoid WYC-209 sensitizes multiple myeloma to carfilzomib via epigenetically upregulating ZMYND

Author:Xu, Jiaxuan; Yan, Jie; Zhang, Haoyu; Dong, Jiahui; Wu, Yue; Qian, Jiajia; Zhao, Quan; Dong, Xiaoqing; Chen, Bing

Journal: EXPERIMENTAL HEMATOLOGY & ONCOLOGY. 2026; Vol. 15, Issue 1, pp. -. DOI: 10.1186/s40164-026-00770-8

4
Functional xenogeneic hematopoietic cells maintaining donor-dominant identity and immune tolerance enable therap

Author:Xiong, Shumin; Zhou, Ren; Wei, Chuijin; Wang, Xiaomin; Tang, Yunhan; Dong, Liaoliao; Yu, Ping; Pei, Duanqing; Chen, Zhu; Chen, Sai-Juan; Cheng, Lin

Journal: EXPERIMENTAL HEMATOLOGY & ONCOLOGY. 2026; Vol. 15, Issue 1, pp. -. DOI: 10.1186/s40164-026-00767-3

5
Novel non-viral in vivo CAR-T therapies: latest updates from the 2025 ASH annual meetin

Author:Xue, Bin; Liu, Yifan; Liang, Aibin; Zhang, Wenjun

Journal: EXPERIMENTAL HEMATOLOGY & ONCOLOGY. 2026; Vol. 15, Issue 1, pp. -. DOI: 10.1186/s40164-026-00765-5

6
Prospects and advances of PROTAC in the treatment of hematologic malignancie

Author:Wang, Xinyang; Zhang, Ming; Mei, Heng

Journal: EXPERIMENTAL HEMATOLOGY & ONCOLOGY. 2026; Vol. 15, Issue 1, pp. -. DOI: 10.1186/s40164-026-00759-3

7
Systematic and precise interventions for KRAS-mutant cancer

Author:Liang, Jinghui; Wu, Junxi; Zhang, Yuan; Wang, Hongyu; Zheng, Yiyang; He, Qing

Journal: EXPERIMENTAL HEMATOLOGY & ONCOLOGY. 2026; Vol. 15, Issue 1, pp. -. DOI: 10.1186/s40164-026-00763-7

8
Efficacy and safety of ruxolitinib for graft-versus-host disease prophylaxis in patients with aplastic anemia undergoing PBSC-only allogeneic stem cell transplantation: a prospective phase II stud

Author:Zhang, Xiaoyu; Pan, Lulu; Zhao, Yanhong; Ma, Runzhi; Zhang, Lining; Zhang, Ying; Li, Gang; Zhai, Weihua; Ma, Qiaoling; Pang, Aiming; Yang, Donglin; Feng, Sizhou; Zhang, Ping; He, Yi; Qin, Guoyou; Jiang, Erlie; Han, Mingzhe

Journal: EXPERIMENTAL HEMATOLOGY & ONCOLOGY. 2026; Vol. 15, Issue 1, pp. -. DOI: 10.1186/s40164-026-00753-9

9
Tertiary lymphoid structures correlate with reduced recurrence risk and enhanced antitumor immunity in esophageal squamous cell carcinoma with pathologic non-complete response to neoadjuvant chemoimmunotherap

Author:Wo, Yang; Lu, Tong; Yang, Zijiang; Li, Xiongfei; Wang, Zheyi; Peng, Yizhou; Shen, Xuxia; Hou, Feng; Jiao, Wenjie; Sun, Yihua

Journal: EXPERIMENTAL HEMATOLOGY & ONCOLOGY. 2026; Vol. 15, Issue 1, pp. -. DOI: 10.1186/s40164-026-00748-6

10
Matrix stiffness induces Ca2+-DCLK1-PIP5K1A mechanotransduction as a context-specific amplifier in pancreatic cancer progression and chemotherapy resistanc

Author:Zhang, Haoxiang; Zhao, Chuanbing; Chen, Jiaoshun; Hu, Xiaoqing; Bai, Jianwei; He, Long; Deng, Zanglong; Yin, Tao

Journal: EXPERIMENTAL HEMATOLOGY & ONCOLOGY. 2026; Vol. 15, Issue 1, pp. -. DOI: 10.1186/s40164-026-00756-6


在线咨询

Experimental Hematology & Oncology

国际简称:EXP HEMATOL ONCOL参考译名:实验血液学和肿瘤学

年发文量:92 CiteScore:19.6 是否预警:否 Gold OA文章占比:100.00% 研究类文章占比:63.04%

杂志社联系方式:CAMPUS, 4 CRINAN ST, LONDON, ENGLAND, N1 9XW

Experimental Hematology & Oncology